Forbion raises in excess of €2 billion for two new funds
15 oct. 2024 01h00 HE
|
Forbion
Forbion’s largest fundraising to date with Forbion’s Growth Opportunities Fund III raising €1.2 billion & Forbion Ventures Fund VII raising €890 million
Amber Therapeutics Closes $100 Million Series A Financing to Advance Breakthrough Amber-UI Neuromodulation Therapy for Mixed Urinary Incontinence towards US FDA Approval
10 juin 2024 03h00 HE
|
Amber Therapeutics
US approval would make Amber-UI the first fully implantable adaptive neuromodulation therapy for women with mixed urinary incontinence (MUI)By targeting the pudendal nerve, Amber-UI has the unique...
Cerevance Adds $47 Million in Series B-1 Extension to Advance Robust Clinical Pipeline
25 avr. 2024 08h00 HE
|
Cerevance
Financing round led by Agent Capital, Bioluminescence, and Double Point Ventures, with participation from new investors MQB Partners and others Proceeds will advance Cerevance’s first-in-class...
ALX Oncology Realigns Executive Leadership Team
06 sept. 2023 08h00 HE
|
ALX Oncology
Jason Lettmann appointed as Chief Executive OfficerDr. Jaume Pons transitions to Chief Scientific Officer SOUTH SAN FRANCISCO, Calif., Sept. 06, 2023 (GLOBE NEWSWIRE) -- ALX Oncology Holdings...
Relievant Medsystems Raises $50 Million to Advance the Treatment for Chronic Vertebrogenic Low Back Pain
19 avr. 2023 09h00 HE
|
Relievant Medsystems, Inc.
MINNEAPOLIS, April 19, 2023 (GLOBE NEWSWIRE) -- Relievant Medsystems, a company dedicated to transforming the diagnosis and treatment of vertebrogenic pain, a type of chronic low back pain (CLBP),...
Catamaran Bio Announces Preclinical Data from Allogeneic CAR-NK Cell Therapy Pipeline for Solid Tumors to be Presented at the American Association for Cancer Research (AACR) Annual Meeting 2023
11 avr. 2023 08h00 HE
|
Catamaran Bio Inc.
Two allogeneic CAR-NK cell therapies demonstrate significant efficacy in tumor xenograft models Data underscore potential of TAILWIND® platform to create effective CAR-NK treatments for solid tumors ...
Cerevance Expands Series B Financing with Additional $51 Million
13 févr. 2023 08h30 HE
|
Cerevance
Proceeds will advance Cerevance’s potential first-in-class programs developed using proprietary NETSseq platform CVN424 for Parkinson’s disease will advance to Phase 2 monotherapy study in Q2 2023 ...
Volta Medical Secures €36M in Series B Funding to Support Adoption of its AI Software for Cardiac Ablation, New CFO Introduced
05 janv. 2023 08h00 HE
|
Volta Medical
New round of financing led by Vensana Capital will support technology platform expansion and further validating VX1, Volta’s Artificial Intelligence (AI) Decision-Support Software in improving...
MaxCyte Signs Strategic Platform License with Catamaran Bio to Support its CAR-NK Cell Therapy Programs
03 janv. 2023 16h05 HE
|
MaxCyte, Inc
ROCKVILLE, Md., Jan. 03, 2023 (GLOBE NEWSWIRE) -- MaxCyte, Inc., (Nasdaq: MXCT; LSE: MXCT), a leading commercial cell-engineering company providing enabling platform technologies to advance...
Carrick Therapeutics Closes Series C Financing
01 déc. 2022 08h05 HE
|
CARRICK THERAPEUTICS LIMITED
Raised $25 million from a Series C financing Proceeds to advance development of first-in-class oncology pipeline across multiple indications DUBLIN, Ireland and BOSTON, Dec. 01, 2022 (GLOBE...